Proactiveinvestors United Kingdom Evgen Pharma https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Evgen Pharma RSS feed en Wed, 22 May 2019 21:35:27 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190522133248_14083840/ Wed, 22 May 2019 13:32:48 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190522133248_14083840/ <![CDATA[RNS press release - Share Option Exercise and Issue of Equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190521070003_14080886/ Tue, 21 May 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190521070003_14080886/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190509174928_14068869/ Thu, 09 May 2019 17:49:28 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190509174928_14068869/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190509101112_14068102/ Thu, 09 May 2019 10:11:12 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190509101112_14068102/ <![CDATA[RNS press release - Result of GM and Completion of Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190508112925_14066640/ Wed, 08 May 2019 11:29:25 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190508112925_14066640/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190426110530_14053628/ Fri, 26 Apr 2019 11:05:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190426110530_14053628/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190426110022_14053616/ Fri, 26 Apr 2019 11:00:22 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190426110022_14053616/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190424113705_14050265/ Wed, 24 Apr 2019 11:37:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190424113705_14050265/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190424113310_14050257/ Wed, 24 Apr 2019 11:33:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190424113310_14050257/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423140541_14048739/ Tue, 23 Apr 2019 14:05:41 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423140541_14048739/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423140029_14048734/ Tue, 23 Apr 2019 14:00:29 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423140029_14048734/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423103033_14048275/ Tue, 23 Apr 2019 10:30:33 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190423103033_14048275/ <![CDATA[RNS press release - Posting of Circular and Timing of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190418173001_14047118/ Thu, 18 Apr 2019 17:30:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190418173001_14047118/ <![CDATA[RNS press release - Placing and Notice of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190417130001_14044975/ Wed, 17 Apr 2019 13:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190417130001_14044975/ <![CDATA[RNS press release - finnCap publishes initiation research ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190402090005_14025100/ Tue, 02 Apr 2019 09:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190402090005_14025100/ <![CDATA[RNS press release - Poster presentation of Imperial College data ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190328070024_14018722/ Thu, 28 Mar 2019 07:00:24 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190328070024_14018722/ <![CDATA[News - Evgen Pharma soars as flagship SFX-01 drug sails through mid-stage breast cancer study ]]> https://www.proactiveinvestors.co.uk/companies/news/217098/evgen-pharma-soars-as-flagship-sfx-01-drug-sails-through-mid-stage-breast-cancer-study-217098.html Shares in Evgen Pharma PLC (LON:EVG) boomed on Monday morning after its SFX-01 drug sailed through a mid-stage breast cancer study.

The purpose of the Phase II trial was to confirm the “mild and favourable” side effect profile of the drug, which it did.

But researchers were also able to show “conclusive evidence of anti-cancer activity” with the disease not getting any worse in a quarter of the 46 patients over the six months of treatment.

READ: Evgen dives as losses widen

Impressively, two of the patients saw their tumours shrink by more than a third over the course of the trial.

The plan now is to test SFX-01 alongside a hormone therapy which investigators think could make a successful cancer-fighting team.

“The clinical benefit observed is very encouraging and we have a high level of confidence that it will perform even better when used to delay the resistance to a newly presented second-line hormone therapy,” said chief executive Stephen Franklin.

“Apart from meeting the primary endpoints, we can also report that of the 46 patients in the trial, 13 registered for the compassionate use programme enabling access to the drug after completion of the study and the longest period for which a patient-derived clinical benefit was an outstanding 448 days.”

Shares soared by more than 20% to 25.0p at the opening bell on Monday.

]]>
Mon, 25 Mar 2019 08:37:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217098/evgen-pharma-soars-as-flagship-sfx-01-drug-sails-through-mid-stage-breast-cancer-study-217098.html
<![CDATA[RNS press release - SFX-01 meets primary endpoints in STEM trial ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190325070012_14013407/ Mon, 25 Mar 2019 07:00:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190325070012_14013407/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190318140103_14006129/ Mon, 18 Mar 2019 14:01:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190318140103_14006129/ <![CDATA[RNS press release - Update on SFX-01 trial read-out dates ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190318070005_14004994/ Mon, 18 Mar 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190318070005_14004994/ <![CDATA[RNS press release - SFX-01 data published in peer reviewed journal ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190305070010_13989812/ Tue, 05 Mar 2019 07:00:10 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190305070010_13989812/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190206153004_13960762/ Wed, 06 Feb 2019 15:30:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190206153004_13960762/ <![CDATA[RNS press release - Clinical trial update confirms read-outs on track ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190205070005_13957901/ Tue, 05 Feb 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190205070005_13957901/ <![CDATA[RNS press release - Grant of Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190130172856_13952473/ Wed, 30 Jan 2019 17:28:56 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190130172856_13952473/ <![CDATA[RNS press release - SFX-01 featured in Nature Reviews Drug Discovery ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190123070005_13943384/ Wed, 23 Jan 2019 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190123070005_13943384/ <![CDATA[RNS press release - Change of Adviser ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190122070010_13942029/ Tue, 22 Jan 2019 07:00:10 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20190122070010_13942029/ <![CDATA[RNS press release - Share option exercise and issue of equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181219180212_13910405/ Wed, 19 Dec 2018 18:02:12 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181219180212_13910405/ <![CDATA[News - Evgen Pharma shares dive as losses widen ]]> https://www.proactiveinvestors.co.uk/companies/news/211061/evgen-pharma-shares-dive-as-losses-widen-211061.html Evgen Pharma PLC (LON:EVG) shares dived on Wednesday after it reported slightly wider first half losses.

The drug development group said its total losses widened to £1.8mln in the six months to the end of September compared to a loss of £1.7mln a year ago. Its net cash outflow fell to £1.5mln from £1.7mln last time, while its cash and short-term investments were flat at £2.2mln.

READ: Evgen Pharma raises £2.3mln to fund its two clinical trials

Evgen said it had not generated any revenue during the period, given it focused on the discovery of new drugs.

"We were delighted with the positive breast cancer interim data showing good tolerability and efficacy in this very difficult to treat patient population and are hopeful that these trends will be maintained in the final analysis,” CEO Stephen Franklin said in a statement.

“With final read-outs of the STEM and SAS clinical trials due in the first and second quarter of 2019 respectively we are excited about the near-term prospects of the company," he added,

Analysts at Northland Capital Partners said news on the STEM trial represented a “key inflection point” for the company.

“Evgen holds a leading position in the therapeutic use of sulforaphane and we expect Evgen to be involved in any future use of sulforaphane in these indications,” they said.

Shares in Evgen were 12% down at 14.75p in early afternoon trade.

]]>
Wed, 12 Dec 2018 13:27:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211061/evgen-pharma-shares-dive-as-losses-widen-211061.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181212070002_13900092/ Wed, 12 Dec 2018 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181212070002_13900092/ <![CDATA[RNS press release - Nominated Adviser Status ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181210150003_13898040/ Mon, 10 Dec 2018 15:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181210150003_13898040/ <![CDATA[RNS press release - Poster Presentation of SFX-01 and Trial Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181204070006_13889881/ Tue, 04 Dec 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181204070006_13889881/ <![CDATA[RNS press release - Notification of Half Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181203070008_13888015/ Mon, 03 Dec 2018 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181203070008_13888015/ <![CDATA[RNS press release - Investor Presentation in Manchester ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181119070006_13871054/ Mon, 19 Nov 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181119070006_13871054/ <![CDATA[RNS press release - Directorate Changes ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181108070016_13859323/ Thu, 08 Nov 2018 07:00:16 +0000 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181108070016_13859323/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181023095754_13838905/ Tue, 23 Oct 2018 09:57:54 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181023095754_13838905/ <![CDATA[RNS press release - Placing ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181018070008_13833114/ Thu, 18 Oct 2018 07:00:08 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20181018070008_13833114/ <![CDATA[RNS press release - Investor Symposium ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180918070004_13793947/ Tue, 18 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180918070004_13793947/ <![CDATA[RNS press release - Notice of Investor Symposium ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180911070018_13785562/ Tue, 11 Sep 2018 07:00:18 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180911070018_13785562/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726152250_13733152/ Thu, 26 Jul 2018 15:22:50 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726152250_13733152/ <![CDATA[RNS press release - AGM Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726070022_13731777/ Thu, 26 Jul 2018 07:00:22 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180726070022_13731777/ <![CDATA[RNS press release - Final Patient Recruited in STEM Phase IIa Trial ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180725070005_13729973/ Wed, 25 Jul 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180725070005_13729973/ <![CDATA[RNS press release - Grant of share options, issue of equity and TVR ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180710110003_13712146/ Tue, 10 Jul 2018 11:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180710110003_13712146/ <![CDATA[RNS press release - Posting of Annual Report and AGM Notice ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180621123003_13688939/ Thu, 21 Jun 2018 12:30:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180621123003_13688939/ <![CDATA[RNS press release - Full Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180613070006_13677202/ Wed, 13 Jun 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180613070006_13677202/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090530_13674198/ Mon, 11 Jun 2018 09:05:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090530_13674198/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090022_13674180/ Mon, 11 Jun 2018 09:00:22 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611090022_13674180/ <![CDATA[RNS press release - Interim Update on STEM Trial ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611070003_13673651/ Mon, 11 Jun 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180611070003_13673651/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607164031_13671646/ Thu, 07 Jun 2018 16:40:31 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607164031_13671646/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607163514_13671638/ Thu, 07 Jun 2018 16:35:14 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180607163514_13671638/ <![CDATA[RNS press release - Notification of Preliminary Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180530070010_13658960/ Wed, 30 May 2018 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/14248/LSE20180530070010_13658960/